Category: Pediatric MS

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults…

Stuart Schlossman

Vitamin D supplementation recommended in all children, teens

SAN FRANCISCO – Vitamin D deficiency is common among children and adolescents, particularly those with chronic disease, Catherine Gordon, MD, said…

Stuart Schlossman

Understanding MS in children

There are several Pediatric MS centers of Excellence in the USA . The information showing below pertains to one of…

Stuart Schlossman

Novartis multiple sclerosis therapy Fingolimod granted FDA Breakthrough Therapy designation for pediatric MS

Breakthrough Therapy designation can expedite the development and review of therapies for serious conditions(1)– In a pivotal Phase III study,…

Stuart Schlossman

Pediatric & Adult MS Share Many Genetic Variants

11.07.17 Pediatric and adult multiple sclerosis (MS) share many genetic variants suggesting similar biological processes are present, a recent study…

Stuart Schlossman

Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a

OCT 28, 2017 PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on…

Stuart Schlossman

Pediatric MS Center information updated

Pediactric MS Centers Doctors and Specialists For a listing of USA pediatric MS Centers, please click here MS Views and…

Stuart Schlossman

Iron Intake Could Contribute to Pediatric Multiple Sclerosis

SEPTEMBER 07, 2017 Rachel Lutz A significant intake of iron may contribute to multiple sclerosis (MS) in children, according to…

Stuart Schlossman

Management of Children with Multiple Sclerosis

Stuart Schlossman

Understanding Multiple Sclerosis (MS) in Children and Teens

Stuart Schlossman